Ozempic for Kidney Disease: What the FDA Approval Means

A New Chapter for Kidney Health: The FDA’s Ozempic Approval

A significant development in healthcare has offered a new layer of hope for millions. In January 2025, the U.S. Food and Drug Administration (FDA) expanded the approved use of Ozempic (semaglutide) to include reducing the risk of worsening kidney disease, kidney failure and death from cardiovascular causes in adults living with both type 2 diabetes and chronic kidney disease (CKD).

This is more than just a headline; it marks a pivotal moment in how these interconnected conditions are managed. For those navigating the complexities of diabetes and kidney health, this news provides a new, evidence-based option to discuss with their healthcare team. This article will break down what this approval means, the science behind it, and what practical next steps might look like. Consult your healthcare provider before starting any medication.

The Intimate Link: Type 2 Diabetes and Chronic Kidney Disease

To understand the importance of this FDA decision, it’s helpful to first understand the relationship between type 2 diabetes (T2D) and chronic kidney disease (CKD). Our kidneys act as sophisticated filters, cleaning waste from our blood. In people with type 2 diabetes, persistently high blood sugar levels can damage the small blood vessels within these filters.

Over time, this damage makes the kidneys less efficient. They may start to leak important proteins, like albumin, into the urine, which is an early sign of trouble. If left unmanaged, this can progress, reducing the kidneys' ability to function and potentially leading to kidney failure.

Because of this strong link, managing blood sugar, blood pressure, and cholesterol is the cornerstone of protecting kidney health in people with diabetes. This approval adds another tool aimed at slowing that progression and lowering cardiovascular risk, which is also high in this population.

What Did the FDA Actually Approve?

The FDA’s language is always precise, and it's important to understand the specifics. This isn't a new drug, but rather a new, approved use—or "indication"—for an existing one.

The Specifics of the New Indication

According to the US prescribing information, Ozempic is now indicated "to reduce the risk of sustained eGFR decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes mellitus and chronic kidney disease." (eGFR is a measure of how well your kidneys filter blood.) For this use, the label's target dose is 1 mg once weekly.

This is separate from Ozempic's earlier approval to reduce the risk of major adverse cardiovascular events (heart attack, stroke or cardiovascular death) in adults with type 2 diabetes and established heart disease.

The kidney approval is specifically for adults who have both type 2 diabetes and chronic kidney disease. It is a US approval; in other countries, including the UK and India, check the local prescribing information with your doctor. It’s intended to be used as part of a comprehensive care plan that also addresses other risk factors, such as high blood pressure and cholesterol.

The Evidence Behind the Decision

This decision wasn’t made lightly. It is based on the results of a major international clinical trial called FLOW (Flowing to Further Cardiovascular Outcomes in Renal Patients with Diabetes).

FLOW enrolled 3,533 adults with T2D and CKD, most already taking standard kidney-protecting medicines (an ACE inhibitor or ARB), who received semaglutide 1 mg weekly or placebo and were followed for a median of about 3.4 years. It was designed to see if semaglutide could do more than just lower blood sugar. The primary outcome was a combination of a large sustained drop in kidney function (eGFR down by 50% or more), kidney failure (including dialysis or transplant), or death from kidney or cardiovascular causes. This happened to 18.7% of people on semaglutide and 23.2% on placebo, a 24% lower relative risk.

This high-quality evidence showed a meaningful benefit for the kidneys and heart in this specific group of people. The label notes the benefit was not clearly seen in the small number of people already taking an SGLT2 inhibitor, though there were few events in that group.

How Does Ozempic Work in This Context?

Ozempic belongs to a class of medications known as glucagon-like peptide-1 (GLP-1) receptor agonists. At its core, it mimics a natural gut hormone that helps the body regulate blood sugar by stimulating insulin release when needed.

However, researchers have discovered that the benefits of GLP-1 agonists go beyond glucose control. While the exact mechanisms are still being fully explored, it's understood that these medications also have positive effects that contribute to heart and kidney protection. They may help reduce inflammation, lower blood pressure, and promote weight loss—all of which ease the burden on the cardiovascular system and the kidneys. This multi-faceted action is likely why it proved so effective in the FLOW trial.

What This Means for You

For individuals and families affected by type 2 diabetes and CKD, this news can be a source of optimism. It represents a shift towards more proactive and protective care.

A New, Proactive Option

For years, the main strategy was to aggressively manage blood sugar and blood pressure to slow down kidney damage. This approval provides a medication that has been shown to reduce the risk of progression. It gives doctors and patients a new, proven tool to add to their treatment plan, potentially changing the long-term outlook for many.

The Importance of a Holistic Approach

It is crucial to remember that medication is only one piece of the puzzle. A healthy lifestyle remains the foundation of managing both T2D and CKD. This includes a kidney-friendly diet, regular physical activity, and not smoking. Lifestyle changes are foundational, and programs that support individuals in making those sustainable shifts can work alongside medication to improve overall health. This new approval complements, rather than replaces, these essential self-care practices.

Key Considerations and Next Steps

If you are living with type 2 diabetes and chronic kidney disease, this news may prompt you to think about your own treatment plan. The most important step is to have an informed conversation with the healthcare professional who knows your health history best.

Talking With Your Doctor

This is a perfect opportunity to check in with your doctor or endocrinologist. You can prepare for the conversation by thinking about a few questions:

• Given my specific health profile, could this medication be a suitable option for me?
• What are the potential benefits and risks in my case?
• How would this fit in with the other medications I am currently taking?
• What side effects should I be aware of?

A Personalized Decision

Healthcare is deeply personal. A treatment that is right for one person may not be right for another. The decision to start any new medication involves weighing the potential benefits against the potential risks and side effects, such as nausea or other gastrointestinal issues. For people with kidney disease, vomiting or diarrhoea can cause dehydration and a sudden worsening of kidney function, so contact your doctor promptly if you cannot keep fluids down. Other label warnings include pancreatitis, gallbladder disease, low blood sugar if you also take insulin or a sulfonylurea, worsening diabetic eye disease (retinopathy) in people who already have it, and a US boxed warning about thyroid C-cell tumours. Seek urgent medical help for severe stomach pain that does not go away (sometimes spreading to your back), or signs of a serious allergic reaction. This is a decision that you and your doctor will make together, based on your kidney function, blood sugar levels, cardiovascular risk, and overall health goals.

This FDA approval represents a validated, scientific step forward in protecting the long-term health of people with diabetes and kidney disease. It’s an encouraging development that underscores the power of research to provide new strategies for managing chronic conditions. As always, the path forward is one of partnership with your healthcare team. Consult your healthcare provider before starting any medication.

Sources

• Ozempic (semaglutide) US Prescribing Information, sections 1 and 14.3: https://www.novo-pi.com/ozempic.pdf
• CNN — FDA approves Ozempic to reduce risks from chronic kidney disease in diabetes patients (28 January 2025): https://kvia.com/health/cnn-health/2025/01/28/fda-approves-ozempic-to-reduce-risks-from-chronic-kidney-disease-in-diabetes-patients/
• Perkovic et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW), N Engl J Med 2024 — PubMed: https://pubmed.ncbi.nlm.nih.gov/38785209/
• NIDDK: Diabetic Kidney Disease: https://www.niddk.nih.gov/health-information/diabetes/overview/preventing-problems/diabetic-kidney-disease